Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
14 août 2017 05h55 HE
|
H. Lundbeck A/S
Valby, Denmark, 2017-08-14 11:55 CEST (GLOBE NEWSWIRE) --
Valby, Denmark, 14 August 2017 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely...
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
10 août 2017 09h09 HE
|
H. Lundbeck A/S
Valby, Denmark, 2017-08-10 15:09 CEST (GLOBE NEWSWIRE) --
Valby, Denmark, 10 August 2017 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely...
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i H. Lundbeck A/S
10 août 2017 09h09 HE
|
H. Lundbeck A/S
Valby, Danmark, 2017-08-10 15:09 CEST (GLOBE NEWSWIRE) --
Valby, Danmark, 10. august 2017 - H. Lundbeck A/S (Lundbeck) skal herved offentliggøre og indberette ledende medarbejderes og disses...
Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017
09 août 2017 00h55 HE
|
H. Lundbeck A/S
Valby, Denmark, 2017-08-09 06:55 CEST (GLOBE NEWSWIRE) --
HIGHLIGHTS
Revenue reached DKK 8,494 million in the first six months of 2017 representing an increase of 13% compared to the...
Lundbeck collaborates on large first-of-its kind study of links between genetics and psychiatric disorders
02 août 2017 02h00 HE
|
H. Lundbeck A/S
Valby, 2017-08-02 08:00 CEST (GLOBE NEWSWIRE) --
H. Lundbeck A/S (Lundbeck) joins personal genetics company 23andMe, Inc. and think tank the Milken Institute in a large new study to increase the...
Lundbeck samarbejder om stort banebrydende studie af sammenhænge mellem gener og psykiatriske lidelser
02 août 2017 02h00 HE
|
H. Lundbeck A/S
Valby, 2017-08-02 08:00 CEST (GLOBE NEWSWIRE) --
H. Lundbeck A/S (Lundbeck) går sammen med gentest-firmaet 23andMe, Inc. og tænketanken the Milken Institute i et nyt stort studie, som skal øge...
Abilify Maintena® (aripiprazol) godkendes af de amerikanske sundheds-myndigheder (FDA) til vedligeholdelsesbehandling af bipolar I lidelse i monoterapi
28 juil. 2017 10h36 HE
|
H. Lundbeck A/S
Den første FDA-godkendte månedlige, langtidsvirkende, injicerbare behandling til vedligeholdelsesbehandling af bipolar I lidelse I hos voksne1,2
Den nye indikation for Abilify Maintena er...
Abilify Maintena® (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder
28 juil. 2017 10h36 HE
|
H. Lundbeck A/S
First FDA-approved, once-monthly, long-acting injectable for the maintenance monotherapy treatment of bipolar I disorder in adults1,2
New indication for Abilify Maintena is based on studies...
Lundbeck og Takeda modtager Complete Respose Letter fra de amerikanske sundhedsmyndigheder (FDA) på deres supplerende registreringsansøgning for Trintellix® (vortioxetin)
22 juin 2017 20h30 HE
|
H. Lundbeck A/S
Valby, Danmark og Osaka, Japan, 23. juni 2017 - H. Lundbeck A/S (Lundbeck) og Takeda Pharmaceutical Company Limited (Takeda) annoncerede i dag, at efter indsendelse af yderligere analyseresultater,...
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix® (vortioxetine) sNDA
22 juin 2017 20h30 HE
|
H. Lundbeck A/S
Valby, Denmark and Osaka, Japan, 23 June 2017 - H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today announced that after providing additional analysis, the U.S. Food...